Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ArQule

- PMLiVE

Mismanagement of Cancer Drugs Fund “unacceptable”

Influential committee of MPs finds the government still unable to assess CDF's patient benefit

Harnessing complexity

Companion diagnostics in oncology

- PMLiVE

Merck & Co’s oral hepatitis C therapy approved in US

Fixed-dose combination Zepatier wins a licence from the FDA

Roche Basel Switzerland

Roche shares slip as profits miss expectations

But shows solid sales growth thanks to its oncology portfolio

- PMLiVE

Germany’s Merck triumphs in court battle with US namesake

English court rules Merck & Co breached the firms' naming agreement

EISAI

Eisai’s Lenvima gets FDA priority review for kidney cancer

The oncology treatment could now be approved in the US before the summer

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

Roche Basel Switzerland

Roche prepares to file atezolizumab for bladder cancer

Imminent submission to the FDA after additional positive phase II trial results

- PMLiVE

Keytruda bounces back in rivalry with Opdivo

First drug in its class to secure FDA approval as a first-line therapy for malignant melanoma

- PMLiVE

MSD appoints Jessica Fine as UK external affairs director

She joins the UK pharma company from Lexington Health

- PMLiVE

Merck finally bags FDA approval for Bridion

Follows three unsuccessful attempts to gain a US licence for the drug

- PMLiVE

FDA panel rejects cardiovascular outcomes claim for Vytorin

Merck & Co fail to convince regulator's advisors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links